Supplementary Figures 1-5 from Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor–Induced Tyrosine Kinase Inhibitor Resistance in &lt;i&gt;EGFR&lt;/i&gt; Mutant Lung Cancer